期刊文献+

腺相关病毒介导β淀粉样肽单链抗体对动物阿尔茨海默病的治疗效果

Therapeutic Effect of Anti-amyloid β Peptide Single-chain Antibody Gene Mediated by Adeno-associated Virus on Animal Alzheimer's Disease
下载PDF
导出
摘要 目的观察携带β淀粉样肽单链抗体基因的腺相关病毒对阿尔茨海默病动物模型的治疗效果。方法给突变淀粉样蛋白前体转基因阿尔茨海默病模型小鼠腿部肌肉注射携带Aβ单链抗体基因的腺相关病毒,在药物注射前和注射后3、7、10个月用Morris水迷宫测定潜伏期,并在药物注射后10个月取大脑做组织切片,行免疫组织化学染色,观察淀粉样斑块在海马的沉积。结果注射基因治疗药物后3个月,阿尔茨海默病模型小鼠的学习和记忆能力明显改善,注射基因治疗药物后10个月,模型小鼠海马淀粉样斑块的沉积减少。结论肌肉注射携带Aβ单链抗体基因的腺相关病毒对阿尔茨海默病模型有治疗作用。 Objective To investigate the therapeutic effect of recombinant adeno-associated virus carrying anti-amyloid β peptide single-chain antibody gene on Alzheimer's disease(AD) in animal models.Methods The recombinant adeno-associated viruses were injected to the leg muscle of mutant amyloid precursor protein transgenic AD mice.The latency of the mice in Morris water maze was tested before and 3,7,10 months after drug administration.The animal brains were harvested 10 months after drug administration and sectioned for amyloid plaques staining.Results The learning and memory abilities of AD model mice were improved significantly 3 months after gene drug administration.Ten months after gene therapy,the numbers of amyloid plaque in hippocampus of model mice decreased.Conclusion The adeno-associated virus carrying anti-amyloid β peptide single-chain antibody gene has therapeutic effect on AD in model mice.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2011年第2期151-155,221,共6页 Acta Academiae Medicinae Sinicae
基金 国家自然科学基金(30500573 30670741)~~
关键词 阿尔茨海默病 腺相关病毒 Β淀粉样肽 单链抗体 Alzheimer's disease adeno-associated virus amyloid β peptide single-chain antibody
  • 相关文献

参考文献17

  • 1Yoshihara T, Takiguchi S, Kyuno A, et al. Immunoreactivi- ty of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro [ J]. J Biochem, 2008, 143 (4) :475-486.
  • 2Pride M, Seubert P, Grundman M, et al. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-assoeiated meningoen- cephalitis [J]. Neurodegener Dis, 2008, 5 (3-4):194- 196.
  • 3Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease [ J]. Expert Opin Biol Ther, 2008, 8(5):633-642.
  • 4Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta [J]. J Neurosci, 2005, 25(3) :629-636.
  • 5Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hem- orrhage after passive anti-Abeta immunotherapy [ J ]. Sci- ence, 2002, 298 (5597) : 1379.
  • 6Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immu- notherapy against Abeta in aged APP-transgenic mice rever- ses cognitive deficits and depletes parenchymal amyloid de- posits in spite of increased vascular amyloid and microhemor- rhage [J]. J Neuroinflamm, 2004, 1(1):24.
  • 7Cai J, Wang S, Zhong Y, et al. Screening and characteriza- tion of human single-chain Fv antibody against beta-amyloid peptide 40 [J]. Neuroreport, 2003, 14(2) :265-268.
  • 8蔡炯,王世真,彭勇,钟彦伟,姬志娟,袁建刚,强伯勤.阿尔茨海默病Aβ人抗体可变区片段基因的克隆和表达[J].中国医学科学院学报,2003,25(5):557-562. 被引量:6
  • 9Liu R, Yuan B, Emadi S, et al. Single chain variable frag- ments against beta-amyloid (Abeta) can inhibit Abeta aggre- gation and prevent abeta-induced neurotoxicity [ J]. Bio- chemistry, 2004, 43(22):6959-6967.
  • 10Manoutcharian K, Acero G, Munguia ME, et al. Human single chain Fv antibodies and a complementarity determi- ning region-derived peptide binding to amyloid-beta 1-42 [J]. Neurobiol Dis, 2004, 17(1) :114-121.

二级参考文献12

  • 1Selkoe DJ. Translating cell biology into therapeutics advances in Alzheimer's disease. Nature 1999, 399(Suppl):A23-A31
  • 2Klein WL, Krafft GA, Finch CE. Targeting small Aβoligomer's: the solution to an Alzheimer's disease conundrum? Trends Neurosci, 2001, 24(4):219-224
  • 3Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature, 2002, 415(31):462
  • 4Du Y, Dodel R, Hampel H, et al. Reduced level of amyloid β peptide antibody in Alzheimer's disease.Neurology, 2001, 57(5):801-805
  • 5Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid β peptide: a potential treatment for Alzheimer's disease. Ann Neurol, 2002, 52:253-256
  • 6Marks JD, Hoogenboom HR, Bonnert TP, et al. Bypassing immunization, and human antibodies from V-gene libraries displayed on phage. J Mol Biol, 1991, 222:581-597
  • 7Hoogenboom HR, Brue AP, Hufton SE, et al. Antibody phage display technology and its application. Immunotechnology, 1998, 4(1):1-20
  • 8蔡炯,王世真.放射免疫显像与治疗.见:甄永苏,邵荣光主编.抗体工程药物.北京:化学工业出版社,2002.262-271
  • 9Agdeppa ED, Kepe V, Petric A, et al. Torsionally modified FDDNP analogs have picomolar binding affinity to plaques in Alzheimer's disease. J Nucl Med, 2002, 43(5):166P
  • 10Wengenack TM, Curran GL, Poduslo JF. Targeting Alzheimer amyloid plaques in vivo. Nature Biotechnology, 2000, 18(8):868-872

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部